Pipeline
We seek various opportunities for the healthy and happy lives of people around the world.
Antibody biosimilars
| Project Name | Ingredient | Original drug | Indication | Development Status |
|---|---|---|---|---|
| OC-P39 | Omalizumab | XOLAIR® | Asthma, hives | preparing |
| OC-P41 | Denosumab | PROLIA® | Osteoporosis, bone loss | preparing |
| OC-P43 | Ustekinumab | STELARA® | Psoriasis, Crohn’s disease, ulcerative colitis, etc. | preparing |
| OC-P42 | Aflibercept | EYLEA® | diabetic macular edema | preparing |
| OC-P47 | Tocilizumab | ACTEMRA® | rheumatoid arthritis | preparing |
* About registered trademark of reference products
XOLAIR® is a registered trademark of NOVARTIS
AVASTIN® is a registered trademark of GENENTECH
PROLIA® is a registered trademark of AMGEN
STELARA® is a registered trademark of JANSSEN
EYLEA® is a registered trademark of REGENERON and BAYER
ACTEMRA® is a registered trademark of CHUGAI SEIYAKU
Antibody New Drugs
| Project Name | Indication | Development Status |
|---|---|---|
| OC-P27 | Pandemic/seasonal flu | preparing |
| OC-P63 | Corona Virus Infectious Disease-19 | preparing |
chemical new drug
| Project Name | Indication | Development Status |
|---|---|---|
| OC-G20 | Hypertrophic cardiomyopathy | preparing |